NEW YORK (GenomeWeb) – Voyager Therapeutics this week announced that it has licensed the non-exclusive rights to use Regenx Biosciences' proprietary adeno-associated viral vectors in three of its drug-development programs, including one focused on an expressed RNAi treatment for monogenic amyotrophic lateral sclerosis (ALS).

The arrangement also gives Voyager rights to use Regenx's vectors to develop therapies for Friedreich's ataxia and Huntington's disease (HD).

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.

Popular Mechanics reports that Caltech researchers have built a prototype nanobot using DNA.

The Sacramento Bee writes that direct-to-consumer genetic testing connected a woman to sperm donor-conceived half siblings.

In PLOS this week: gene expression catalog for sheep, viral diversity among respiratory samples from camels, and more.